Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Could long Covid be solved by autoantibodies?

Swiss researchers have found a new class of ‘good autoantibodies’, which are associated with a favourable course and lower risk of long-Covid.

autoantibodies

Researchers from Istituto Di Ricerca In Biomedicina (IRB), Switzerland, discovered autoantibodies in Covid patients. “Previously it had been observed that autoantibodies are common in severe Covid patients, those who end up in intensive care,” said Jonathan Muri, postdoctoral fellow at the Institute for Research in Biomedicine (IRB, affiliated with the Università della Svizzera italiana). “Instead, in this case we discovered the opposite.”

As seem in Nature Immunology, the autoantibodies in question neutralise chemokines, molecules that direct immune cell trafficking. “Chemokines are a bit like traffic lights: they tell our immune cells when and where to go in the case of an infection so that they can fight it” added coauthor Valentina Cecchinato, also at the IRB.

“In the presence of the autoantibodies, the traffic lights are blocked and the influx of the cells that make inflammation chronic decreases.” In short, it helps to turn off the inflammatory response.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The team also analysed blood from patients recovering after Covid-19 from two other hospitals, with the same result.

But how does blocking the immune response help in Covid?

“The immune system in some cases is a double-edged sword,” explained Mariagrazia Uguccioni, another co-director of the study, “it is important to activate it promptly to neutralise the coronavirus, but it must also be turned off at the right time, otherwise it can do damage.”

In fact, what usually brings patients to the hospital is excessive inflammation induced by the infection. Autoantibodies against chemokines could have a beneficial anti-inflammatory effect.

Davide Robbiani, co-director of the study and director of the IRB, concluded that “for now we can say that the presence of these ‘good autoantibodies’ is associated with a milder course and a lower risk that symptoms will continue for a long time,” as observed in many patients who unfortunately still suffer for weeks or even months after Covid-19.